No deworming drug, whether formulated for dogs or humans, has been proven to cure cancer in people. The claim gained traction after a viral social media story in 2018, and there is real laboratory research showing that benzimidazole compounds can kill cancer cells in dishes and slow tumors in some animal experiments. But “kills cancer cells in a lab” is a very different statement from “cures cancer in a living person,” and the handful of human clinical trials conducted so far have produced underwhelming results. The gap between the hype and the evidence is wide enough to be dangerous for anyone considering swapping their oncologist’s treatment plan for a veterinary pill.
Where the Claim Came From
The story most people encounter involves a man named Joe Tippens, an Oklahoma resident who was diagnosed with small-cell lung cancer that had spread throughout his body. According to his widely shared blog posts and media interviews, Tippens began taking fenbendazole, a deworming drug sold for dogs and livestock, alongside conventional treatment. His cancer went into remission. The story spread rapidly on social media, YouTube, and online cancer forums, eventually going viral in South Korea and other countries where fenbendazole sales spiked dramatically.
What often gets lost in the retelling is that Tippens was also receiving an experimental immunotherapy drug in a clinical trial, and he continued conventional cancer treatment throughout. He did not simply take a dog dewormer and watch his tumors disappear. A single person’s experience, no matter how compelling, cannot establish that a drug works, because there is no way to know which treatment was responsible, whether the cancer would have responded to the immunotherapy alone, or whether something else entirely was at play. A published case series of three patients who self-administered fenbendazole acknowledged exactly these limitations, noting that “without controlled clinical trials, it is not possible to establish a causal relationship between FBZ and the observed disease regressions” and that “confounding factors such as concurrent therapies, lifestyle interventions, or spontaneous remission cannot be excluded.”1Case Reports in Oncology. Fenbendazole for Cancer Treatment: A Case Series of Self-Administration in Three Patients
What Happens in the Lab
The reason the fenbendazole story gained a veneer of scientific credibility is that benzimidazole drugs genuinely do interesting things to cancer cells in laboratory experiments. Fenbendazole, mebendazole, and albendazole all belong to the benzimidazole family, which was originally developed to kill parasitic worms. These drugs work by destabilizing microtubules, the structural scaffolding that cells need to divide. Cancer cells divide rapidly, so a drug that disrupts that machinery can, in theory, interfere with tumor growth.
Lab studies have shown that benzimidazoles affect cancer cells through several pathways beyond just microtubule disruption. They can trigger programmed cell death, halt the cell division cycle, interfere with the formation of new blood vessels that tumors need for growth, and block glucose uptake that fuels cancer cell metabolism.2PubMed Central. The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs A 2018 study specifically on fenbendazole found that the drug caused cancer cells to shift a tumor-suppressing protein called p53 to the mitochondria, triggering a cell-death cascade, while also reducing the cancer cells’ ability to take in glucose.3PubMed Central. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways A review of benzimidazoles in blood cancers similarly catalogued effects on cell cycle arrest, tubulin disruption, and interference with cancer-promoting signaling pathways.4PubMed Central. From Deworming to Cancer Therapy: Benzimidazoles in Hematological Malignancies
These findings are real, reproducible, and published in peer-reviewed journals. They are also incomplete. Thousands of compounds kill cancer cells in a petri dish. Bleach kills cancer cells in a petri dish. The question that matters is whether a drug can selectively target cancer in a living body without unacceptable harm to the patient, and that question can only be answered through clinical trials.
Why Lab Results Do Not Translate Automatically
A cell in a dish and a tumor inside a person exist in radically different environments. When researchers drip fenbendazole directly onto cancer cells in a well plate, the drug is in full contact with its target at a controlled concentration. Inside a living body, the drug has to survive digestion, get absorbed into the bloodstream, reach the tumor in sufficient concentration, and maintain that concentration long enough to do meaningful damage, all while being metabolized by the liver and excreted by the kidneys.
Fenbendazole has notoriously poor absorption in humans. It was designed for the gut environment of livestock, where it needs to reach intestinal parasites without necessarily entering the bloodstream at high levels. Researchers studying albendazole, a related benzimidazole, have explored nanotechnology-based formulations specifically to improve how much drug actually gets into the body and reaches tumors, a challenge that underscores how poorly these compounds perform in their standard oral forms.5PubMed. Nanoformulations of albendazole as effective anticancer and antiparasite agents
Animal studies tell a mixed story. One experiment that fed mice a diet containing fenbendazole at a standard therapeutic dose found that the drug did not alter tumor growth, invasion, or metastasis, and did not change how tumors responded to radiation.6PubMed Central. Use of fenbendazole-containing therapeutic diets for mice in experimental cancer therapy studies That study was originally designed to see if fenbendazole contamination in laboratory animal food could confound cancer experiments, and the answer was no: the drug had no measurable anticancer effect when delivered orally to living animals with active tumors. A separate lab study found that fenbendazole produced additive, not synergistic, effects when combined with radiation or the chemotherapy drug docetaxel, meaning it did not amplify those treatments in any special way.7PubMed Central. Fenbendazole as a Potential Anticancer Drug
The Clinical Trials That Have Been Done
Fenbendazole itself, the veterinary drug, has never been tested in a formal human cancer clinical trial. What has been tested is mebendazole, a closely related benzimidazole that is approved for human use as an antiparasitic. Mebendazole has a well-documented safety profile from decades of use against intestinal worms, which makes it a more practical candidate for drug repurposing than a veterinary-only formulation.8PubMed Central. Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature
Most of the clinical data come from brain cancer. A phase 1 trial enrolled 24 patients with newly diagnosed high-grade gliomas, including 18 with glioblastoma, the most aggressive type. Patients took mebendazole alongside standard chemotherapy with temozolomide. Four patients at the highest dose level developed significantly elevated liver enzymes, which reversed when the dose was lowered or stopped. The median overall survival was 21 months, and about a quarter of patients were alive at three and four years.9PubMed Central. Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial Those numbers are in the range of what standard treatment alone typically achieves for glioblastoma, making it hard to say whether mebendazole contributed anything.
A larger phase 2 randomized trial tested mebendazole in patients with recurrent glioblastoma, a setting where the cancer has already come back after initial treatment and outcomes are generally poor. Patients received mebendazole combined with either temozolomide or lomustine, two standard chemotherapy drugs. The study set a benchmark: if the combination could achieve at least 55% of patients surviving to nine months, it would be considered worth pursuing further. Neither arm met that benchmark. The temozolomide-mebendazole group had about 37% nine-month survival, and the lomustine-mebendazole group reached about 45%.10eClinicalMedicine. Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial In patients with better functional status, the lomustine-mebendazole arm performed somewhat better at around 58% nine-month survival, but overall the trial was considered a failure by its own pre-defined criteria.11Journal of Clinical Oncology. Mebendazole in recurrent glioblastoma: Results of a phase 2 randomized study
Preclinical models have also shown mebendazole activity against breast cancer metastasis in mice, and the drug was described as well-tolerated in its phase 1 glioma trial.12PubMed Central. Mebendazole prevents distant organ metastases in part by decreasing ITGβ4 expression and cancer stemness But mouse models and early-phase safety trials are a long way from an effective cancer therapy. As things stand, no professional oncology organization recommends mebendazole or fenbendazole as a cancer treatment.
Real Safety Risks of Self-Medicating
People who take fenbendazole for cancer are usually buying veterinary products over the counter or online, without a prescription and without medical supervision. Veterinary formulations are not manufactured to the same purity and consistency standards as human pharmaceuticals, and the doses people choose are often based on anecdotal recommendations from online forums rather than any pharmacological reasoning.
The liver is the most immediate concern. A case report described a 67-year-old woman who developed severe drug-induced liver injury after self-administering fenbendazole. She presented with two weeks of jaundice, and a biopsy confirmed a hepatocellular pattern of damage directly attributable to the drug. Her liver function tests took three months to normalize after she stopped taking it.13PubMed Central. Severe Drug-Induced Liver Injury Due to Self-administration of the Veterinary Anthelmintic Medication, Fenbendazole Even in the controlled setting of the mebendazole clinical trial with standardized dosing and regular monitoring, liver enzyme elevations were a dose-limiting problem that required intervention.9PubMed Central. Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial
There is also the risk of drug interactions. Many cancer patients are on chemotherapy, immunotherapy, corticosteroids, and various supportive medications. Adding a benzimidazole without medical oversight creates the potential for unpredictable interactions that could either reduce the effectiveness of proven treatments or amplify toxicity. A patient who develops liver injury from fenbendazole, for instance, may have to pause or modify their actual cancer treatment while the damage heals.
The Bigger Danger of Replacing Conventional Treatment
Perhaps the most serious risk is not from the dewormer itself but from what people give up in order to take it. Research has consistently shown that cancer patients who use alternative medicine in place of conventional treatment have significantly worse outcomes. A study from the National Cancer Institute compared patients who chose alternative medicine exclusively with matched patients who received standard treatment. Those who chose alternative medicine had roughly two and a half times the risk of death overall, and the effect was far worse in certain cancers: about five and a half times the risk in breast cancer and about four and a half times in colorectal cancer.14PubMed. Use of Alternative Medicine for Cancer and Its Impact on Survival
An earlier study found a similar pattern, with alternative medicine users experiencing higher death rates than non-users. The association was strongest in patients who were otherwise in good health at diagnosis, precisely the group with the most to lose from delaying or refusing effective treatment.15PubMed. Does use of alternative medicine predict survival from cancer? These studies do not prove that alternative medicines cause death directly. They show that patients who reject or delay standard care in favor of unproven alternatives die sooner, often from cancers that were highly treatable at the stage when they were diagnosed.
This does not mean every patient taking fenbendazole is refusing chemotherapy. Many add it on top of their standard regimen. But the online communities that promote fenbendazole frequently cast doubt on conventional oncology, and the people most vulnerable to that messaging are the ones who are frightened, desperate, or running out of options. For those patients, the decision to invest time, money, and hope in an unproven drug can delay or displace real treatment at a critical window.
Other Antiparasitic Drugs in Cancer Research
Fenbendazole is not the only antiparasitic drug that has attracted attention in oncology. Ivermectin, a widely used antiparasitic in both human and veterinary medicine, has gone through a similar cycle of promising lab results followed by disappointment at the clinical level. Preclinical studies show that ivermectin can inhibit cancer cell proliferation and trigger cell death through several signaling pathways. But a recent review noted that clinical evidence in humans is essentially absent, with no large-scale randomized controlled trials confirming any therapeutic benefit, and described a “critical translational gap between preclinical results and practical clinical application.”16PubMed. Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential?
The broader field of drug repurposing, taking existing approved medications and testing them against new diseases, is a legitimate and active area of cancer research. Metformin (a diabetes drug), statins (cholesterol-lowering drugs), and aspirin have all been investigated as potential anticancer agents. What separates serious repurposing research from social media hype is the insistence on rigorous clinical trials before declaring that something “works.” A review of drug repurposing in veterinary oncology catalogued the challenges that apply equally to human medicine: limited funding, ethical and regulatory hurdles, and the need for well-designed trials involving multiple institutions.17PubMed Central. Drug Repurposing in Veterinary Oncology: Myth or Reality?
Why Online Communities Are So Persuasive
One reason the fenbendazole story persists despite the thin evidence is the way information moves through online cancer forums and social media groups. When someone shares a story of remission and credits a deworming drug, it lands with enormous emotional force. The story has a protagonist, a plot, and a happy ending. A randomized controlled trial has none of those things. A phase 2 study that “failed to achieve the pre-set benchmark” does not generate the same viral momentum as a man who says a dog pill saved his life.
Research on how cancer patients engage with online forums has found that discussions about complementary and alternative treatments are rated as significantly less trustworthy than discussions about conventional cancer therapies, even by the people participating in those forums.18SpringerLink (Supportive Care in Cancer). Online cancer forums and complementary and alternative medicine in cancer care: effects of ehealth literacy and psychological distress on use and attitudes In other words, patients themselves recognize that the quality of information about alternative treatments online is shaky. But recognition of low trustworthiness does not always prevent people from trying the treatments, especially when conventional options have been exhausted or when side effects of standard therapy feel intolerable.
The psychology is understandable. A cancer diagnosis is terrifying, and conventional treatments are often brutal. A cheap, available, seemingly low-risk pill that “they don’t want you to know about” is an intensely appealing narrative. But the evidence remains stubbornly clear: benzimidazole dewormers have not been shown to cure cancer in any human trial, and the closest relative tested, mebendazole, failed to beat standard care in the most rigorous study conducted to date.
What Patients Considering Fenbendazole Should Know
If you are a cancer patient or a caregiver thinking about fenbendazole, a few practical points are worth considering. First, fenbendazole is not the same drug as mebendazole. They are chemically related but differ in how they are absorbed, metabolized, and eliminated. Almost all the clinical safety data comes from mebendazole; fenbendazole has never been formally studied for safety or dosing in humans with cancer. Second, veterinary products are not interchangeable with human pharmaceuticals. They may contain different inactive ingredients, different concentrations, or impurities that would not pass human-grade manufacturing standards.
Third, and most practically: if you want to explore benzimidazole drugs as part of your cancer treatment, clinical trials are the safest and most productive way to do it. Several trials of mebendazole in different cancers have been conducted, and more may be enrolling. Participating in a trial gives you access to the drug under medical supervision, with regular blood monitoring for liver function and other side effects, and it contributes to the evidence base that could eventually help other patients. Taking a veterinary dewormer from an online retailer based on a YouTube video does none of those things.
Your oncologist is unlikely to be dismissive if you bring up fenbendazole, because the lab data is genuinely interesting and many oncologists are aware of the research. What they will likely tell you is what the evidence says: it has not been shown to work in people, and self-medicating with a veterinary drug carries real risks. That is not a cover-up or closed-mindedness. It is the same standard of evidence that protects patients from the hundreds of other compounds that looked promising in a lab and turned out to be useless, or harmful, in practice.